Literature DB >> 23227282

Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Howard P Monsour1, Catherine T Frenette, Kathleen Wyne.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in western society and is increasing in parallel with the worldwide epidemic of obesity. It exists in a simple form, steatosis, or a more complex and more dangerous form, steatohepatitis, and it is often but not always associated with the metabolic syndrome. NAFLD can progress to cirrhosis and hepatocellular carcinoma. It is responsible for the majority of cryptogenic cirrhosis cases. Increasingly, NAFLD and its more sinister form, steatohepatitis, have been linked to the increased incidence of cardiovascular disease (CVD) worldwide, independent of the metabolic syndrome. Death from CVD surpasses death from liver complications, but that is beginning to change as people are living longer with CVD. In this article, we will review nonalcoholic fatty liver disease and its epidemiology, prevalence, pathology, and link to CVD.

Entities:  

Keywords:  cardiovascular disease; fatty liver disease; metabolic syndrome; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Mesh:

Year:  2012        PMID: 23227282      PMCID: PMC3487573          DOI: 10.14797/mdcj-8-3-21

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  39 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

Review 2.  The role of non-alcoholic fatty liver disease in cardiovascular disease.

Authors:  Gianluca Perseghin
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

3.  The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Valeriya Lyssenko; Tiinamaija Tuomi; Ralph A Defronzo; Leif Groop
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

Review 4.  Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Authors:  G Vernon; A Baranova; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-30       Impact factor: 8.171

5.  Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.

Authors:  Kristin D Kistler; Elizabeth M Brunt; Jeanne M Clark; Anna Mae Diehl; James F Sallis; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2011-01-04       Impact factor: 10.864

6.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

7.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

8.  Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.

Authors:  V M Struben; E E Hespenheide; S H Caldwell
Journal:  Am J Med       Date:  2000-01       Impact factor: 4.965

Review 9.  Nonalcoholic steatohepatitis: definition and pathology.

Authors:  E M Brunt
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

10.  Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

Authors:  Elizabeth K Speliotes; Laura M Yerges-Armstrong; Jun Wu; Ruben Hernaez; Lauren J Kim; Cameron D Palmer; Vilmundur Gudnason; Gudny Eiriksdottir; Melissa E Garcia; Lenore J Launer; Michael A Nalls; Jeanne M Clark; Braxton D Mitchell; Alan R Shuldiner; Johannah L Butler; Marta Tomas; Udo Hoffmann; Shih-Jen Hwang; Joseph M Massaro; Christopher J O'Donnell; Dushyant V Sahani; Veikko Salomaa; Eric E Schadt; Stephen M Schwartz; David S Siscovick; Benjamin F Voight; J Jeffrey Carr; Mary F Feitosa; Tamara B Harris; Caroline S Fox; Albert V Smith; W H Linda Kao; Joel N Hirschhorn; Ingrid B Borecki
Journal:  PLoS Genet       Date:  2011-03-10       Impact factor: 5.917

View more
  5 in total

Review 1.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 2.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.

Authors:  Sandra Milić; Davorka Lulić; Davor Štimac
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 3.  Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review.

Authors:  Abdulrahman Ismaiel; Dan L Dumitraşcu
Journal:  Front Med (Lausanne)       Date:  2019-09-13

4.  Assessment of the association between body composition and risk of non-alcoholic fatty liver.

Authors:  Mohammad Ariya; Farbod Koohpayeh; Alireza Ghaemi; Saeed Osati; Sayed Hossain Davoodi; Jalaledin Mirzay Razzaz; Gholamali Javedan; Elham Ehrampoush; Reza Homayounfar
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

5.  Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.

Authors:  Yun Shen; Xiaojing Ma; Jian Zhou; Xiaoping Pan; Yaping Hao; Mi Zhou; Zhigang Lu; Meifang Gao; Yuqian Bao; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2013-08-28       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.